

**The Australian Securities Exchange
Companies Announcement Office
SYDNEY NSW 2000**

15 March, 2012

Dear Sir/Madam

Notification of Amendment to Timetable for commencement of Re-admission to Official List

Probiomics (“Company”, ASX: PCC) expects that the re-admission of the Company to the ASX Official List, and the re-commencement of trading in the Company’s securities on ASX, will be completed in accordance with the following indicative timetable:

Event	Originally proposed date	Amended date
Close of Public Offer Period	6 February, 2012	27 February, 2012
Close of Takeover Bid Period	16 March, 2012	23 March, 2012
Last day for registration of transfers in the Company’s securities on a pre-Share Consolidation basis	-	23 March, 2012
Share Consolidation on a 1:20 basis	21 March, 2012	27 March, 2012
Issue of: <ul style="list-style-type: none"> • Public Offer Shares and Public Offer Options; • Bid Consideration, being Consolidated Probiomics Shares and Replacement Probiomics Options; and • Director Options and Probiomics Performance Executive Options 	19 March, 2012	28 March, 2012
Completion of dispatch of new holding statements to relevant Probiomics securityholders to reflect: <ul style="list-style-type: none"> • the issue of the Probiomics Securities referred to in the immediately above row; and • changes in holdings of Probiomics Securities as a result of the Share Consolidation 	28 March, 2012	29 March, 2012
Re-commencement of quotation of the Company’s shares and options on the ASX Official List	-	4 April, 2012
Change in the Company’s name to “Bioxyne Limited” becomes effective	30 March, 2012	10 April, 2012



As at the date of this announcement, there is no proposal to alter the date of any other Event referred to in the “Important Dates” at the commencement of the Bidder’s Statement issued by the Company and dated 13 December, 2011.

The Company however reserves the right to vary the date of any Event referred to in the “Important Dates”, including the date of any of the Events referred to in the table immediately above.

Yours sincerely,

A handwritten signature in blue ink, appearing to read 'A. Jairath', with a horizontal line underneath the name.

A Jairath,
Company Secretary

Probiomics Limited

Probiomics has proprietary ownership of a unique probiotic strain – PCC[®]

PCC[®] has been clinically proved to have superior qualities to other probiotic strains – particularly in promoting systemic immune response.

Probiomics’ commercial objective is to earn royalties from licensing PCC[®] to distribution companies selling products in global markets.